Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 453

1.

Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families.

Eerola H, Heinonen M, Heikkilä P, Kilpivaara O, Tamminen A, Aittomäki K, Blomqvist C, Ristimäki A, Nevanlinna H.

Breast Cancer Res. 2008;10(1):R17. doi: 10.1186/bcr1863. Epub 2008 Feb 14.

2.

Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers.

Aaltonen K, Blomqvist C, Amini RM, Eerola H, Aittomäki K, Heikkilä P, Nevanlinna H.

Clin Cancer Res. 2008 Apr 1;14(7):1976-83. doi: 10.1158/1078-0432.CCR-07-4100.

3.

Cyclin D1 expression analysis in familial breast cancers may discriminate BRCAX from BRCA2-linked cases.

Colombo M, Giarola M, Mariani L, Ripamonti CB, De Benedetti V, Sardella M, Losa M, Manoukian S, Peissel B, Pierotti MA, Pilotti S, Radice P.

Mod Pathol. 2008 Oct;21(10):1262-70. doi: 10.1038/modpathol.2008.43. Epub 2008 Mar 7.

4.

Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type.

Foulkes WD, Metcalfe K, Sun P, Hanna WM, Lynch HT, Ghadirian P, Tung N, Olopade OI, Weber BL, McLennan J, Olivotto IA, Bégin LR, Narod SA.

Clin Cancer Res. 2004 Mar 15;10(6):2029-34.

5.

Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer.

Arnes JB, Brunet JS, Stefansson I, Bégin LR, Wong N, Chappuis PO, Akslen LA, Foulkes WD.

Clin Cancer Res. 2005 Jun 1;11(11):4003-11.

6.

Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.

Palacios J, Honrado E, Osorio A, Cazorla A, Sarrió D, Barroso A, Rodríguez S, Cigudosa JC, Diez O, Alonso C, Lerma E, Sánchez L, Rivas C, Benítez J.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3606-14.

PMID:
14506147
7.

The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications.

Honrado E, Benítez J, Palacios J.

Mod Pathol. 2005 Oct;18(10):1305-20. Review.

8.

BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.

Ottini L, Masala G, D'Amico C, Mancini B, Saieva C, Aceto G, Gestri D, Vezzosi V, Falchetti M, De Marco M, Paglierani M, Cama A, Bianchi S, Mariani-Costantini R, Palli D.

Cancer Res. 2003 Jan 15;63(2):342-7.

9.

The molecular pathology of hereditary breast cancer.

Palacios J, Robles-Frías MJ, Castilla MA, López-García MA, Benítez J.

Pathobiology. 2008;75(2):85-94. doi: 10.1159/000123846. Epub 2008 Jun 10. Review.

10.

Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Graeser MK, Engel C, Rhiem K, Gadzicki D, Bick U, Kast K, Froster UG, Schlehe B, Bechtold A, Arnold N, Preisler-Adams S, Nestle-Kraemling C, Zaino M, Loeffler M, Kiechle M, Meindl A, Varga D, Schmutzler RK.

J Clin Oncol. 2009 Dec 10;27(35):5887-92. doi: 10.1200/JCO.2008.19.9430. Epub 2009 Oct 26.

PMID:
19858402
11.

Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.

Collins LC, Martyniak A, Kandel MJ, Stadler ZK, Masciari S, Miron A, Richardson AL, Schnitt SJ, Garber JE.

Am J Surg Pathol. 2009 Jul;33(7):1093-7. doi: 10.1097/PAS.0b013e31819c1c93.

PMID:
19390427
12.

Reproductive factors in hereditary breast cancer.

Jernström HC, Johannsson OT, Loman N, Borg A, Olsson H.

Breast Cancer Res Treat. 1999 Dec;58(3):295-301.

PMID:
10718491
13.

Analysis of breast cancer susceptibility genes BRCA1 and BRCA2 in Thai familial and isolated early-onset breast and ovarian cancer.

Patmasiriwat P, Bhothisuwan K, Sinilnikova OM, Chopin S, Methakijvaroon S, Badzioch M, Padungsutt P, Vattanaviboon P, Vattanasapt V, Szabo C, Saunders GF, Goldgar D, Lenoir GM.

Hum Mutat. 2002 Sep;20(3):230.

PMID:
12203997
14.

High risk of contralateral breast carcinoma in women with hereditary/familial non-BRCA1/BRCA2 breast carcinoma.

Shahedi K, Emanuelsson M, Wiklund F, Gronberg H.

Cancer. 2006 Mar 15;106(6):1237-42.

15.

Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers.

van der Groep P, van Diest PJ, Menko FH, Bart J, de Vries EG, van der Wall E.

J Clin Pathol. 2009 Oct;62(10):926-30. doi: 10.1136/jcp.2009.065524. Epub 2009 Jun 18.

PMID:
19541683
16.

Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer.

Zhang J, Pei R, Pang Z, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.

Breast Cancer Res Treat. 2012 Apr;132(2):421-8. doi: 10.1007/s10549-011-1596-x. Epub 2011 May 26.

PMID:
21614564
17.

Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent.

Oros KK, Ghadirian P, Maugard CM, Perret C, Paredes Y, Mes-Masson AM, Foulkes WD, Provencher D, Tonin PN.

Clin Genet. 2006 Oct;70(4):320-9.

PMID:
16965326
18.

Novel BRCA1/2 mutations in Serbian breast and breast-ovarian cancer patients with hereditary predisposition.

Dobricić J, Branković-Magić M, Filipović S, Radulović S.

Cancer Genet Cytogenet. 2010 Oct 1;202(1):27-32. doi: 10.1016/j.cancergencyto.2010.06.001.

PMID:
20804917
19.

Tumour biological features of BRCA1-induced breast and ovarian cancer.

Jóhannsson OT, Idvall I, Anderson C, Borg A, Barkardóttir RB, Egilsson V, Olsson H.

Eur J Cancer. 1997 Mar;33(3):362-71.

PMID:
9155518

Supplemental Content

Support Center